Point72 DIFC Ltd bought a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,895 shares of the company’s stock, valued at approximately $140,000.
Other hedge funds have also added to or reduced their stakes in the company. Principal Financial Group Inc. increased its stake in shares of Castle Biosciences by 2.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after acquiring an additional 40,377 shares in the last quarter. Bellevue Group AG grew its holdings in Castle Biosciences by 3.7% in the third quarter. Bellevue Group AG now owns 1,262,030 shares of the company’s stock worth $35,993,000 after purchasing an additional 44,929 shares during the period. Portolan Capital Management LLC raised its holdings in shares of Castle Biosciences by 3.7% during the third quarter. Portolan Capital Management LLC now owns 1,255,628 shares of the company’s stock valued at $35,811,000 after purchasing an additional 44,676 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Castle Biosciences by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company’s stock worth $17,631,000 after purchasing an additional 60,675 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Castle Biosciences by 828.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 499,192 shares of the company’s stock valued at $14,237,000 after buying an additional 445,415 shares during the period. 92.60% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
CSTL has been the topic of a number of research reports. Lake Street Capital upped their price target on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Robert W. Baird increased their target price on Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. BTIG Research boosted their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Scotiabank raised their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 6th. Finally, KeyCorp boosted their target price on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $37.88.
Insider Activity at Castle Biosciences
In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $29.44, for a total transaction of $231,604.48. Following the completion of the transaction, the director now directly owns 5,700 shares of the company’s stock, valued at approximately $167,808. This represents a 57.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Frank Stokes sold 6,923 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $29.93, for a total value of $207,205.39. Following the transaction, the chief financial officer now directly owns 30,823 shares in the company, valued at $922,532.39. This represents a 18.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,213 shares of company stock worth $752,673. 7.20% of the stock is owned by company insiders.
Castle Biosciences Trading Down 3.0 %
NASDAQ:CSTL opened at $31.19 on Monday. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The firm has a 50-day moving average price of $31.19 and a two-hundred day moving average price of $26.95. The firm has a market cap of $873.63 million, a price-to-earnings ratio of 155.96 and a beta of 0.92. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14. The firm had revenue of $85.78 million during the quarter, compared to the consensus estimate of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same quarter in the prior year, the company earned ($0.26) EPS. On average, equities analysts expect that Castle Biosciences, Inc. will post 0.34 earnings per share for the current fiscal year.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Read More
- Five stocks we like better than Castle Biosciences
- What is a SEC Filing?
- Guidewire Software Provides Long-Awaited Buying Opportunity
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- What’s Behind These 3 Recent Analyst Stock Upgrades?
- How to trade using analyst ratings
- Fast-Growing Companies That Are Still Undervalued
Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report).
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.